Myovant Sciences Revenue and Competitors

Claim your profile

Location

$200M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Myovant Sciences's estimated annual revenue is currently $144.9M per year.(i)
  • Myovant Sciences received $86.2M in venture funding in July 2018.
  • Myovant Sciences's estimated revenue per employee is $202,444
  • Myovant Sciences's total funding is $200M.
  • Myovant Sciences's current valuation is $1.4B. (January 2022)

Employee Data

  • Myovant Sciences has 716 Employees.(i)
  • Myovant Sciences grew their employee count by 13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant's lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women's health and endocrine-related disorders. For more information, please visit the company's website at myovant.com.

keywords:N/A

$200M

Total Funding

716

Number of Employees

$144.9M

Revenue (est)

13%

Employee Growth %

$1.4B

Valuation

N/A

Accelerator

Myovant Sciences News

2022-04-20 - Myovant: Poised To Overcome Regulatory Issues

The steep decline in Myovant Sciences share price is due to an FDA notice regarding relugolix label expansion for endometriosis.

2022-04-20 - Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal ...

Myovant Sciences is a healthcare company focused on redefining care through differentiated solutions in high unmet need areas within women's...

2022-04-06 - Myovant Sciences and Pfizer Provide Update on ...

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative...

2019-09-12 - Is Something Really Weird Happening In Myovant Sciences Ltd. (MYOV), Office Depot (ODP)

The recent performance of Myovant Sciences Ltd. (NYSE:MYOV) stock in the market spoke loud and clear to investors as MYOV saw more than ...

2019-09-07 - $3B package deal to push Peninsula company into arms of Japanese drugmaker

Former hedge fund partner Vivek Ramaswamy's collection of "vants" — including Brisbane-based, women's health-focused Myovant Sciences ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$261.4M738N/AN/A
#2
$35M7667%N/A
#3
$265.8M775N/AN/A
#4
$76.6M84121%$574.9M
#5
$260.9M8473%N/A

Myovant Sciences Funding

DateAmountRoundLead InvestorsReference
2017-10-17$140.0MUndisclosedNovaQuest Capital ManagementArticle
2018-07-12$86.2MUndisclosedJ.P. Morgan Securities LLCArticle